Summit lead asset beats Merck’s Keytruda in a first in lung cancer

seekingalpha05-31

Summit Therapeutics (NASDAQ:SMMT) traded higher on Thursday after the company said its lead asset, ivonescimab, became the first to outperform Merck’s (NYSE:MRK) ant-PD1 immunotherapy Keytruda in a ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2439367487?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1623197589/image_1623197589.jpg","is_english":true,"pubTime":"2024-05-31 03:12","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2439367487","market":"us","top_or_hot":-1,"title":"Summit lead asset beats Merck’s Keytruda in a first in lung cancer","media":"seekingalpha","content":"<div>\n<p>Summit Therapeutics (NASDAQ:SMMT) traded higher on Thursday after the company said its lead asset, ivonescimab, became the first to outperform Merck’s (NYSE:MRK) ant-PD1 immunotherapy Keytruda in a ...</p>\n\n<a href=\"https://seekingalpha.com/news/4111700-summit-stock-gains-lead-asset-beats-keytruda\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Summit lead asset beats Merck’s Keytruda in a first in lung cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSummit lead asset beats Merck’s Keytruda in a first in lung cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-05-31 03:12 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4111700-summit-stock-gains-lead-asset-beats-keytruda><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Summit Therapeutics (NASDAQ:SMMT) traded higher on Thursday after the company said its lead asset, ivonescimab, became the first to outperform Merck’s (NYSE:MRK) ant-PD1 immunotherapy Keytruda in a ...</p>\n\n<a href=\"https://seekingalpha.com/news/4111700-summit-stock-gains-lead-asset-beats-keytruda\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999002232.USD","symbol_name":"Allianz Global High Payout USD","start_time":0,"source_url":"https://seekingalpha.com/news/4111700-summit-stock-gains-lead-asset-beats-keytruda","article_id":"2439367487","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1623197589/image_1623197589.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2439367487","pubTimestamp":1717096322,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Summit Therapeutics  traded higher on Thursday after the company said its lead asset, ivonescimab, became the first to outperform Merck’s  ant-PD1 immunotherapy Keytruda in a late-stage trial for non-small cell lung cancer . Merck  shares reached a session low in reaction, while Summit  witnessed over threefold rise in value.  Citing interim data from its China-based HARMONi-2 Phase 3 trial, Summit  said ivonescimab, a bispecific antibody blocking the PD-1 receptor in cancer cells, met its primary endpoint of progression-free survival  as a first-line therapy. HARMONi-2, conducted by its Chinese partner Akeso , was designed to evaluate ivonescimab against Keytruda, also known as pembrolizumab, in patients with locally advanced or metastatic NSCLC. Florida-based Summit  said the PFS advantage was seen across different patient groups, including those with low or high PD-L1 expression and squamous or non-squamous histologies. Full results from the trial are expected at a medical event lat","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"SG9999002232.USD":"Allianz Global High Payout USD","LU0234572021.USD":"高盛美国核心股票组合Acc","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","SG9999002224.SGD":"Allianz Global High Payout SGD","AKESF":"AKESO INC.","LU0965509010.AUD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (AUDHDG) INC","SG9999014559.SGD":"United Income Focus Trust Dis SGD","LU2461242641.AUD":"WELLINGTON US QUALITY GROWTH \"A\" (AUDHDG) ACC","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","SG9999014567.USD":"UOB UNITED INCOME FOCUS TRUST FUND (USD) ACC","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU0861579265.USD":"联博低波幅策略股票基金A","BK4516":"特朗普概念","LU0985320562.USD":"NORDEA 1 GLOBAL STARS EQUITY \"BP\" (USD) ACC","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","BK4585":"ETF&股票定投概念","SG9999014542.SGD":"United Income Focus Trust Acc SGD","SMMF":"Summit Financial Group","BK4139":"生物科技","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU0965509101.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (SGDHDG) ACC","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","BK4211":"区域性银行","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU1917777945.USD":"安联专题基金Cl AT Acc","LU0965509283.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (SGDHDG) INC","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","LU0238689110.USD":"贝莱德环球动力股票基金","BK4195":"互助储蓄与抵押信贷金融服务","BK4559":"巴菲特持仓","MRK":"默沙东","BK4588":"碎股","BK4550":"红杉资本持仓","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","PFS":"Provident Financial Services Inc","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","SMMT":"Summit Therapeutics PLC"},"translate_title":"Summit lead asset在肺癌领域首次击败默克公司的Keytruda","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SMMT":1,"AKESF":1,"MRK":1,"PFS":1,"SMMF":1},"content_text":"Summit Therapeutics (NASDAQ:SMMT) traded higher on Thursday after the company said its lead asset, ivonescimab, became the first to outperform Merck’s (NYSE:MRK) ant-PD1 immunotherapy Keytruda in a late-stage trial for non-small cell lung cancer (NSCLC). Merck (MRK) shares reached a session low in reaction, while Summit (SMMT) witnessed over threefold rise in value.  Citing interim data from its China-based HARMONi-2 Phase 3 trial, Summit (SMMT) said ivonescimab, a bispecific antibody blocking the PD-1 receptor in cancer cells, met its primary endpoint of progression-free survival (PFS) as a first-line therapy. HARMONi-2, conducted by its Chinese partner Akeso (OTCPK:AKESF), was designed to evaluate ivonescimab against Keytruda, also known as pembrolizumab, in patients with locally advanced or metastatic NSCLC. Florida-based Summit (SMMT) said the PFS advantage was seen across different patient groups, including those with low or high PD-L1 expression and squamous or non-squamous histologies. Full results from the trial are expected at a medical event later this year. “This is an historic moment for ivonescimab, Team Summit, our partners at Akeso, and most importantly, we believe this is the beginning of a paradigm change for treatment options for patients living with cancer,” CEO Robert Duggan remarked.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2439367487"}